TABLE 3.
Antimicrobial susceptibility of P. aeruginosa bloodstream isolates (n = 305)a
| Antimicrobial(s) | % Susceptible in:
|
||||||
|---|---|---|---|---|---|---|---|
| 1997 (n = 52) | 1998 (n = 53) | 1999 (n = 53) | 2000 (n = 50) | 2001 (n = 50) | 2002 (n = 47) | All years | |
| Cefepime | NFb | 93.8 | 90.6 | 94.0 | 92.1 | 91.5 | 92.3 |
| Ceftazidime | 96.1 | 92.3 | NF | NF | NF | NF | 94.0 |
| Piperacillin-tazobactam | NF | 96.9 | 92.5 | 92.0 | 94.7 | 91.5 | 93.7 |
| Imipenem-cilastatin | 88.5 | 89.2 | 94.3 | 88.0 | 84.2 | 78.7 | 87.5 |
| Ciprofloxacin | 88.5 | 80.0 | 83.0 | 78.0 | 68.4 | 78.7 | 80.0 |
| Gentamicin | 92.3 | 90.8 | 92.5 | 92.0 | 92.1 | 100.0 | 93.1 |
| Tobramycin | 94.2 | 96.9 | 92.5 | 94.0 | 97.4 | 100.0 | 95.7 |
a
Resistance to antimicrobial combinations: cefepime or ceftazidime and aminoglycoside, 2.3%; cefepime or ceftazidime and ciprofloxacin, 4.6%; piperacillin-tazobactam and aminoglycoside, 1.6%; piperacillin-tazobactam and ciprofloxacin, 4%; imipenem-cilastatin and aminoglycoside, 2.3%; imipenem-cilastatin and ciprofloxacin, 5.6%.
b
NF, nonformulary.